In today’s rapidly evolving healthcare landscape, Thermo Fisher Scientific is driving meaningful change. Through advanced diagnostic innovations, the company helps empower clinicians to improve patient outcomes, including in the field of kidney transplantation. Building on Dr. Paul Terasaki’s legacy, Thermo Fisher’s transplant diagnostics business helps accurately match donors with recipients and monitor post-transplant health with greater precision. Their latest pre-transplant risk assessment assay and non-invasive CXCL10 urine test are transforming how nephrologists assess and manage organ rejection. From major hospitals to underserved regions, Thermo Fisher is making life-saving science accessible—shaping the future of transplant care and improving lives across the globe.